STOCK TITAN

Cognition Therapeutics Inc - CGTX STOCK NEWS

Welcome to our dedicated news page for Cognition Therapeutics (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on Cognition Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cognition Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cognition Therapeutics's position in the market.

Rhea-AI Summary
Cognition Therapeutics, Inc. (CGTX) announced that its president and CEO will present at the TD Cowen 44th Annual Health Care Conference to discuss the company's pipeline progress and recent achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced new findings that provide insight into the biology of Alzheimer's disease. The research, conducted by collaborators at the University of Edinburgh, revealed the role of the σ-2 receptor in regulating Aβ oligomer binding. The study utilized high-resolution microscopy techniques to analyze protein-protein interactions in brain samples from individuals with Alzheimer's disease. The results indicate that Aβ oligomers are proximate to certain receptor proteins on the synapse surface, which may form a complex. Additionally, the study confirmed that CT1812, Cognition's lead product candidate, causes the removal of Aβ oligomers from synapses, offering a potential new mechanism to fight Alzheimer's disease progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced the anticipation of topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease and Phase 2 SHIMMER trial in mild-to-moderate dementia with Lewy bodies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
none
Rhea-AI Summary
Cognition Therapeutics, Inc. (Nasdaq: CGTX) releases its seventh Conversations video podcast episode discussing the results from the Phase 2 SEQUEL study on CT1812's effects on synaptic function in Alzheimer’s Disease. Dr. Anthony Caggiano moderates a discussion with leading experts, highlighting the positive impact of CT1812 treatment on synaptic function in adults with mild-to-moderate Alzheimer’s disease, as presented at the CTAD conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
Rhea-AI Summary
Cognition Therapeutics, Inc. (NASDAQ: CGTX) presents in vivo preclinical results at the Society for Neuroscience’s annual meeting, highlighting the role of sigma-2 receptor modulators in Alzheimer's and Parkinson’s diseases. The data reveals the effect of two chemically distinct σ-2 receptor modulators on gene and protein expression in mouse and rat models of the diseases. These findings support the continued discovery and development of candidates targeting this therapeutic area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Cognition Therapeutics, Inc. completed enrollment in the Phase 2 SHINE study of CT1812 for Alzheimer's disease, with top-line results expected in mid-2024. Initial results showed a slowing of cognitive decline and positive safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
clinical trial
Rhea-AI Summary
Cognition Therapeutics, Inc. reported financial results for Q3 2023, with cash and cash equivalents of $33.0 million. The company initiated clinical site enrollment for the Phase 2 START trial for Alzheimer's disease and began dosing in the MAGNIFY trial for dry age-macular degeneration. The CEO expects to report topline results from the Phase 2 SHINE trial in mid-2024 and data from the Phase 2 SHIMMER trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
earnings
-
Rhea-AI Summary
Cognition Therapeutics presents Phase 2 study design of START study at CTAD conference. The study assesses CT1812 in individuals with early Alzheimer’s disease. Combination therapies and the potential benefits of CT1812 are discussed. Clinical data supports CT1812's potential benefits. The START study is actively underway with screening at multiple clinical sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary
Cognition Therapeutics presents EEG findings from Phase 2 SEQUEL study at CTAD conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
none
Rhea-AI Summary
Cognition Therapeutics releases video podcast on dry AMD treatment landscape
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
Cognition Therapeutics Inc

Nasdaq:CGTX

CGTX Rankings

CGTX Stock Data

63.28M
24.63M
7.88%
41.82%
0.45%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Purchase

About CGTX

cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.